SG3 DOC: 08-018

SUBJECT: Transition to ACAM2000 Smallpox Vaccine In late January, DoD begins transition to the use of the ACAM2000 smallpox vaccine, licensed for use in September 2007. All Dryvax vials will expire on 29 February 2008 and logistics personnel will be required to destroy all unused vaccine. The indications for smallpox vaccination remain the same. Clinical screening, safety profile and use of both vaccines is very similar. Important differences include the following: a. ACAM2000 vaccination requires a 15-jab scarification technique for all uses, whether providing an initial vaccination or booster. b. ACAM2000 must be diluted with just 0.3 ml of diluent; though the vial provided contains 0.6 ml. c. ACAM2000 expires 30-days after reconstitution; therefore clinics must be diligent in utilization to minimize vaccine loss. As part of the licensing approval, the FDA mandated that every individual receiving ACAM2000 be provided with the official medication guide developed by the manufacturer. Immunization clinics will receive medication guides with vaccine shipments, and local reproduction of the guide is authorized. Th